Prime Medicine director granted 75,000 stock options
Prime Medicine, Inc. director Wendy Chung reported receiving a grant of stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Prime Medicine, Inc. director Wendy Chung reported receiving a grant of stock options. The award covers 75,000 options to buy Prime Medicine common stock at an exercise price of $3.06 per share, with all 75,000 options shown as held after this grant.
The options vest in full on the earlier of June 5, 2027 or the date of the next annual meeting of stockholders, as long as Chung continues to provide service to the company through that vesting date. The options expire on June 5, 2036 if not exercised.
Insider Trade Summary
Grant/Award: 75,000 shares
Grant/Award
1 txn
Insider
Chung Wendy
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 75,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 75,000 contracts (Direct)
Footnotes (1)
- F1. The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Key Figures
Options granted: 75,000 options
Exercise price: $3.06 per share
Post-grant derivative holdings: 75,000 derivative securities
+2 more
5 metrics
Options granted
75,000 options
Stock Option (right to buy) grant to director
Exercise price
$3.06 per share
Conversion or exercise price for the options
Post-grant derivative holdings
75,000 derivative securities
Total options held after this transaction
Vesting date
Earlier of June 5, 2027 or next annual meeting
Full vesting condition subject to continuous service
Expiration date
June 5, 2036
Option expiration if not exercised
Key Terms
Stock Option (right to buy), derivative securities, exercise price, vesting, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
derivative securities financial
"derivativeTransactionCount: 1 derivative-type records"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
exercise price financial
"conversion_or_exercise_price: 3.0600"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares subject to this option shall vest in full upon the earlier"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
annual meeting of stockholders financial
"earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Prime Medicine (PRME) director Wendy Chung report in this Form 4?
Wendy Chung reported a grant of stock options covering 75,000 shares of Prime Medicine common stock. These options were awarded at a $3.06 exercise price and represent a compensation-related acquisition, not an open-market stock purchase or sale.
How many Prime Medicine (PRME) options were granted to Wendy Chung?
Wendy Chung was granted stock options on 75,000 underlying shares of Prime Medicine common stock. The Form 4 shows 75,000 derivative securities held after the transaction, all tied to this single award reported on the filing date.
What is the exercise price of Wendy Chung’s Prime Medicine (PRME) stock options?
The stock options granted to Wendy Chung carry an exercise price of $3.06 per share. This means she can buy Prime Medicine common stock at $3.06 when the options are vested and exercised, subject to the option terms and expiration date.
When do Wendy Chung’s Prime Medicine (PRME) options vest?
The options vest in full on the earlier of June 5, 2027, or the date of Prime Medicine’s next annual meeting of stockholders. Vesting is conditional on her continuous service to the company through the applicable vesting date, as disclosed.
What is the expiration date of the Prime Medicine (PRME) options granted to Wendy Chung?
The stock options granted to Wendy Chung expire on June 5, 2036. After this expiration date, any unexercised options become worthless, so exercises must occur between vesting and that 2036 expiration under the award’s terms.
Is Wendy Chung’s Form 4 transaction a stock purchase or sale of Prime Medicine (PRME)?
The Form 4 reports a grant of derivative securities, not an open-market stock purchase or sale. The transaction code A reflects a grant or award acquisition of stock options, which may lead to future share purchases upon exercise at $3.06.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates